Sept. 28, 2012 | Vol. 11 No. 191 | Full Issue in PDF Format
View the entire issue.
PhRMA is asking the Supreme Court to take up and overturn the 3rd Circuit Court’s decision that reverse patent settlements between generics and branded drug makers violate antitrust law.
The FDA has approved Bayer HealthCare Pharmaceuticals’ Stivarga to treat patients with metastatic colorectal cancer that has progressed after treatment.
Bristol-Myers Squibb (BMS) and Pfizer have resubmitted their NDA for Eliquis to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
Endo Pharmaceuticals received an FDA untitled letter for omitting cardiovascular (CV) and other serious risks associated with its prostate cancer drug Vantas in a 12-page caregiver brochure.
Forest Laboratories and partner Pierre Fabre Laboratories have submitted an NDA for levomilnacipran to treat major depressive disorder.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.